文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-PSMA-1007 PET局灶性非特异性骨摄取的多中心回顾性评估

Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-06-13

该多中心回顾性研究分析了348例前列腺癌患者的18F-PSMA-1007 PET扫描,发现51.4%的患者存在局灶性非特异性骨摄取(UBU),最常见于肋骨和骨盆。UBU频率与PSA、Gleason评分、肿瘤大小、年龄及注射剂量无关,但在数字PET/CT上显著高于模拟PET/CT。44.7%的UBU对治疗管理有临床影响,随访后部分仍性质不明,提示需谨慎解读以避免过度分期。

要点

  • 18F-PSMA-1007 PET中UBU发生率约51.4%,常见于肋骨和骨盆。
  • 数字PET/CT上UBU频率显著高于模拟PET/CT(82% vs 40.3%)。
  • UBU对44.7%患者的治疗管理有临床影响,需谨慎解读避免过度分期。

核心结论

  • UBU在18F-PSMA-1007 PET/CT检查患者中约占三分之二,数字PET扫描仪上显著更频繁,应谨慎解读以避免过度分期。

研究设计与样本

  • 多中心回顾性分析四中心348例前列腺癌患者的18F-PSMA-1007 PET扫描,定义UBU为SUVmax<10.0的局灶轻中度摄取且无明显良恶性原因。

主要发现

  • 348例中179例(51.4%)存在UBU,最常见于肋骨(57.5%)和骨盆(24.8%)。
  • UBU频率与PSA、Gleason评分、肿瘤大小、年龄及注射剂量无关。
  • 数字PET/CT上UBU频率(82%,n=74)显著高于模拟PET/CT(40.3%,n=221)(p=.0001),数字PET/MR为51%(n=53)(p=.1599)。
  • 179例中80例(44.7%)的UBU解读对治疗管理关键,视为临床相关。
  • 65例UBU有随访:活检3例、放疗伴PSA随访3例、影像随访59例;随访后仍不明确28例(43%)、良性28例(43%)、恶性9例(14%)。

关键数值与推荐

  • UBU定义为SUVmax<10.0的局灶轻中度摄取且无明显良恶性原因。

临床怎么用

  • 对18F-PSMA-1007 PET发现的局灶性骨摄取应结合临床和影像随访谨慎判断,避免将UBU误判为转移导致过度分期。

局限性

  • 回顾性设计,仅65例UBU有随访数据,部分UBU性质仍不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Improved logistics and availability led to a rapid increase in the use of [18F]-PSMA-1007 for prostate cancer PET imaging. Initial data suggests increased uptake in benign lesions compared to [68 Ga]-PSMA-11, and clinical observations found increased unspecific bone uptake (UBU). We therefore investigate the frequency and characteristics of UBU in [18F]-PSMA-1007 PET. METHODS: We retrospectively analyzed [18F]-PSMA-1007 PET scans from four centers for the presence of UBU, defined as a focal mild-to-moderate uptake (SUVmax < 10.0) not obviously related to a benign or malignant cause. If present, up to three leading UBUs were quantified (SUVmax), localized, and correlated to clinical parameters, such as age, PSA, injected dose, Gleason score, tumor size (T1-T4), and type of PET scanner (analog vs. digital). Additionally, clinical and imaging follow-up results and therapeutic impact were evaluated. RESULTS: UBUs were identified in 179 out of 348 patients (51.4%). The most frequent localizations were ribs (57.5%) and pelvis (24.8%). The frequency of UBUs was not associated with PSA, Gleason score, tumor size, age, or the injected [18F]-PSMA-1007 dose. UBUs were significantly more frequent in images obtained with digital PET/CT scans (n = 74, 82%) than analog PET/CT scans (n = 221, 40.3%) (p = .0001) but not in digital PET/MR (n = 53, 51%) (p = .1599). In 80 out of 179 patients (44.7%), the interpretation of UBUs was critical for therapeutic management and therefore considered clinically relevant. For 65 UBUs, follow-ups were available: three biopsies, three radiotherapies with PSA follow-up, and 59 cases with imaging. After follow-up, UBUs were still considered unclear in 28 of 65 patients (43%), benign in 28 (43%), and malignant in nine (14%) patients. CONCLUSION: UBUs occur in two-thirds of patients imaged with [18F]-PSMA-1007 PET/CT and are significantly more frequent on digital PET scanners than analog scanners. UBUs should be interpreted carefully to avoid over-staging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Grünig H, Maurer A, Thali Y, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021. PMID: 34120201. doi:10.1007/s00259-021-05424-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。